Vanguard Global Advisers’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.36M Buy
94,227
+11,515
+14% +$292K ﹤0.01% 1138
2026
Q2
$2.1M Sell
82,712
-1,560
-2% -$36.9K ﹤0.01% 1233
2026
Q1
$1.9M Buy
+84,272
New +$1.87M ﹤0.01% 1228

Other funds holding PCRX

Vanguard Global Advisers's PCRX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Pacira BioSciences (PCRX) stake by 14% in Q3 2026, buying an estimated $292K and bringing the position to 94,227 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

Vanguard Global Advisers first reported a position in PCRX in Q1 2026 and has held it in 3 quarters since. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Vanguard Global Advisers held 94,227 shares of Pacira BioSciences worth $2.36M as of Q3 2026.
  • Vanguard Global Advisers bought 11,515 Pacira BioSciences shares in Q3 2026, an estimated $292K.
  • Pacira BioSciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1138 holding.
  • Vanguard Global Advisers first reported a position in Pacira BioSciences in Q1 2026 and has held it in 3 quarters since.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.